

Metadata of the chapter that will be visualized online

Chapter Title	Dolichyl-Phosphate (UDP- <i>N</i> -Acetylglucosamine) <i>N</i> -Acetylglucosaminephospho transferase 1 (GlcNAc-1-P Transferase) (DPAGT1)	
Copyright Year	2014	
Copyright Holder	Springer Japan	
Corresponding Author	Family Name	Dean
	Particle	
	Given Name	Neta
	Suffix	
	Division/Department	Department of Biochemistry and Cell Biology
	Organization/University	Stony Brook University
	Street	Life Sciences Building
	City	Stony Brook
	State	NY
	Postcode	11794-5215
	Country	USA
	Phone	631-632-9309
	Email	neta.dean@stonybrook.edu
Author	Family Name	Gao
	Particle	
	Given Name	Xiao-Dong
	Suffix	
	Division/Department	The Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology
	Organization/University	Jiangnan University
	Street	1800 Lihu Avenue
	Postcode	214122
	City	Wuxi
	State	Jiangsu Province
	Country	China
	Phone	+86-510-85197003
	Fax	+86-510-85197003
	Email	xdgao@jiangnan.edu.cn
	URL	http://klccb.jiangnan.edu.cn/ketizu1.aspx

Abstract

In eukaryotes, *N*-linked protein glycosylation starts with the synthesis of a highly conserved lipid-linked oligosaccharide (LLO) on the endoplasmic reticulum (ER) membrane. As the committed process of *N*-glycosylation, 14 monosaccharide residues are sequentially transferred onto dolichyl pyrophosphate (dol-P) carrier molecule by a series of glycosyltransferases (GTase) to form the core oligosaccharide precursor $\text{Glc}_3\text{Man}_9\text{GlcNAc}_2\text{-P-P-dol}$. The first half of GTase reactions in LLO synthesis takes place on the cytoplasmic face of ER (Fig. 124.1), which produces $\text{Man}_5\text{GlcNAc}_2\text{-P-P-dol}$ intermediate from the soluble nucleotide sugar substrates uridine diphosphate *N*-acetylglucosamine (UDP-GlcNAc) and guanosine diphosphate *D*-mannose (GDP-man). Once this intermediate is flipped into the lumen of the ER, the next seven sugars are added from dolichol-sugar substrates Man-P-dol and Glc-P-dol to complete the assembly. Another half of GTase catalyzes these reactions (reviewed in Helenius et al. 2004; Kelleher and Gilmore 2006; Weerapana and Imperiali 2006). *DPAGT1* encodes dolichyl-phosphate (UDP-*N*-acetylglucosamine) *N*-acetylglucosaminophosphotransferase 1 that catalyzes the first reaction of LLO synthesis, by adding GlcNAc-1-P from cytoplasmic UDP-GlcNAc to dol-P. *DPAGT1* is essential for *N*-linked protein glycosylation and considered to be a key regulator among the metabolic pathway of protein *N*-glycosylation (Lehrman 1991).

1 **Dolichyl-Phosphate**
2 **(UDP-*N*-Acetylglucosamine)**
3 ***N*-Acetylglucosaminophospho-**
4 **transferase 1 (GlcNAc-1-P**
5 **Transferase) (DPAGT1)** 124

Au4

6 Neta Dean and Xiao-Dong Gao

7 **Contents**

8	Introduction	1
9	Databanks	3
10	Name and History	3
11	Structure	3
12	Enzyme Activity Assay and Substrate Specificity	4
13	Preparation	4
14	Biological Aspects	4
15	Knockout and Transgenic Mice	5
16	Human Disease	5
17	Future Perspectives	5
18	Cross-References	6
19	Further Reading	6
20	References	6

21 **Introduction**

22 In eukaryotes, *N*-linked protein glycosylation starts with the synthesis of a highly
23 conserved lipid-linked oligosaccharide (LLO) on the endoplasmic reticulum (ER)
24 membrane. As the committed process of *N*-glycosylation, 14 monosaccharide
25 residues are sequentially transferred onto dolichyl pyrophosphate (dol-P) carrier
26 molecule by a series of glycosyltransferases (GTase) to form the core

N. Dean (✉)

Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY, USA
e-mail: neta.dean@stonybrook.edu

X.-D. Gao

The Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education,
School of Biotechnology, Jiangnan University, Wuxi, Jiangsu Province, China
e-mail: xdgao@jiangnan.edu.cn

N. Taniguchi et al. (eds.), *Handbook of Glycosyltransferases and Related Genes*,
DOI 10.1007/978-4-431-54240-7_124, © Springer Japan 2014

1




Fig. 124.1 Biosynthetic pathway of lipid-linked oligosaccharides on ER membrane. Shown is a schematic depiction of the sequential assembly of the 14 sugars $\text{Glc}_3\text{Man}_9\text{GlcNAc}_2$ on dolichol pyrophosphate by the Alg (asparagine-linked glycosylation) glycosyltransferases. Seven sugars are added on the cytoplasmic face, and then another seven in the lumen. DPAGT1 (also known as Alg7 glycosyltransferase) catalyzes the first reaction of the assembly, in which GlcNAc-1-P-Dol from UDP-GlcNAc is added to dolichol phosphate (P-Dol) to generate GlcNAc-PP-Dol. The Alg13/Alg14 heterodimeric UDP-GlcNAc transferase then adds the second GlcNAc from UDP-GlcNAc to generate $\text{GlcNAc}_2\text{-PP-Dol}$. The next five mannoses are added sequentially using GDP-man by the Alg1, Alg2, and Alg11 mannosyltransferases, respectively, to generate $\text{Man}_5\text{Glc}_2\text{-PP-Dol}$. This intermediate flips into the lumen, where it is further extended by an additional four mannose and three glucose residues from dolichol-linked sugars. Oligosaccharyltransferase transfers this “core” oligosaccharide from dolichol to nascent polypeptides

27 oligosaccharide precursor $\text{Glc}_3\text{Man}_9\text{GlcNAc}_2\text{-P-P-dol}$. The first half of GTase
 28 reactions in LLO synthesis takes place on the cytoplasmic face of ER
 29 (Fig. 124.1), which produces $\text{Man}_5\text{GlcNAc}_2\text{-P-P-dol}$ intermediate from the
 30 soluble nucleotide sugar substrates uridine diphosphate *N*-acetylglucosamine
 31 (UDP-GlcNAc) and guanosine diphosphate *D*-mannose (GDP-man). Once this
 32 intermediate is flipped into the lumen of the ER, the next seven sugars are
 33 added from dolichol-sugar substrates Man-P-dol and Glc-P-dol to complete
 34 the assembly. Another half of GTase catalyzes these reactions (reviewed in
 35 Helenius et al. 2004; Kelleher and Gilmore 2006; Weerapana and Imperiali 2006).
 36 *DPAGT1* encodes dolichyl-phosphate (UDP-*N*-acetylglucosamine)
 37 *N*-acetylglucosaminephosphotransferase 1 that catalyzes the first reaction of LLO
 38 synthesis, by adding GlcNAc-1-P from cytoplasmic UDP-GlcNAc to dol-P.
 39 *DPAGT1* is essential for *N*-linked protein glycosylation and considered to
 40 be a key regulator among the metabolic pathway of protein *N*-glycosylation
 41 (Lehrman 1991).

Au1

42 Databanks

43 IUBMB enzyme nomenclature: EC 2.7.8.15

Dolichyl-phosphate (UDP-*N*-acetylglucosamine) *N*-acetylglucosaminephosphotransferase 1 (GlcNAc-1-P transferase) (DPAGT1)

	Species	Gene symbol	GenBank accession number	UniProt ID	PDB accession number
t1.2	<i>Homo sapiens</i>	<i>DPAGT1</i>	Z82022	9QH3H5	N/A
t1.3	<i>Saccharomyces cerevisiae</i>	<i>ALG7</i>	Z36112	P07286	N/A

44 Name and History

45 Dolichyl-phosphate (UDP-*N*-acetylglucosamine) *N*-acetylglucosaminephospho-
 46 transferase 1 transfers GlcNAc-P from cytosolic UDP-GlcNAc to dol-P on the ER
 47 membrane to produce GlcNAc-P-P-dol. As shown in Fig. 124.1, this enzyme is
 48 responsible for the first step of LLO biosynthesis. The enzyme activity was first
 49 demonstrated from a solubilized membrane fraction from pig aorta (Heifetz
 50 et al. 1977). Tunicamycin, an antibiotic isolated from *Streptomyces lysosuperficus*,
 51 is a potent inhibitor of DPAGT1 and has been used for identification of *DPAGT1*
 52 genes. The first tunicamycin-resistance gene was identified in yeast (Rine et al. 1983)
 53 and found to correspond to *ALG7* (Barnes et al. 1984). The *DPAGT1* gene
 54 (commonly referred to as *ALG7*) has been also cloned from *Schizosaccharomyces*
 55 *pombe* (Zou et al. 1995), *Leishmania amazonensis* (Liu and Chang 1992), mouse
 56 (Rajput et al. 1992), CHO cells (Zhu and Lehrman 1990), and humans (Eckert et al.
 57 1998). The first purification of DPAGT1 has been done from the lactating mammary
 58 gland of bovine (Shailubhai et al. 1988).

59 Structure

60 Hamster DPAGT1 consists of 408 amino acids and is predicted to have ten mem-
 61 brane-spanning domains (Zhu and Lehrman 1990). Its topological features on ER
 62 membrane have been further elucidated (Dan et al. 1996). The largest hydrophilic
 63 loop between the two C-terminal transmembrane spans, which contains a number of
 64 conserved residues essential for DPAGT1 activity, is identified to the cytosolic face.
 65 Results demonstrated a cytoplasmic orientation of DPAGT1 consisting with the idea
 66 that assembly of GlcNAc-P-P-dol happens on the cytosolic side of ER membrane.
 67 DPAGT1 in vivo exists as a dimer and/or a higher-order structure. In addition to
 68 chemical cross-linking studies that reveal the dimeric form of DPAGT1 (Dan and
 69 Lehrman 1997) in mouse cell lysates, biochemical and genetic analyses demonstrate
 70 that in yeast, Alg7 interacts with the heterodimeric Alg13/14 UDP-GlcNAc transfer-
 71 ase that catalyzes the second step of LLO biosynthesis (Noffz et al. 2009).

72 Enzyme Activity Assay and Substrate Specificity

73 This enzyme catalyzes the following reaction: UDP-*N*-acetyl-D-glucosamine +
74 phosphodolichol \rightleftharpoons *N*-acetyl-D-glucosaminyl-diphosphodolichol + UMP.

75 This reaction requires divalent metals such as Mg²⁺ or Mn²⁺ (Kean 1983; Kaushal
76 and Elbein 1985) and is activated by dol-P-Man and phosphatidylglycerol (Kean 1985;
77 Kaushal and Elbein 1985). Tunicamycin is a well-known inhibitor of DPAGT1 and
78 has been a useful reagent for the study of this enzyme. In addition, the reaction
79 product (i.e., GlcNAc-P-P-dol) as well as the product of the following reaction
80 (i.e., GlcNAc-GlcNAc-P-P-dol) inhibits enzyme activity, suggesting feedback regulation
81 by its product (Kean et al. 1999). UDP-GlcNAc-1-P transferase activity is assayed
82 by using dol-P as acceptor and UDP-[¹⁴C]GlcNAc as the donor. The reaction contained
83 in a final volume of 0.06 ml: 28 mM *tris*-HCl, pH 7.4, 10 mM MgCl₂, 0.7 M NaCl,
84 0.7 mM DTT, 0.3 % Nonidet P40, 3.5 mM diheptanoyl phosphatidylcholine, 23 %
85 glycerol, 0.05 mCi UDP-[¹⁴C]GlcNAc, 2 mg dol-P, and solubilized enzyme (equivalent
86 to 0.2 mg membrane protein). Lipid-linked products are extracted with chloroform/
87 methanol and analyzed by thin layer chromatography (Würde et al. 2012).

88 Preparation

89 *DPAGT1* is found in all eukaryotes. Like other membrane-associated LLO GTases,
90 UDP-GlcNAc-1-P transferase activity is found in the ER microsomal membrane
91 fraction and can be solubilized by extraction with neutral detergents such as Triton
92 X-100 and Nonidet P-40. Because of its purported instability, the enzyme should be
93 stabilized and activated by phospholipids such as phosphatidylglycerol and dolichol
94 phosphate (Plouhar and Bretthauer 1982). There is a report documented,
95 a purification of DPAGT1 from the lactating mammary gland of bovine (Shailubhai
96 et al. 1988). Bovine DPAGT1 can be purified from solubilized microsome
97 preparations with 0.25 % Nonidet P-40 using (NH₄)₂SO₄ precipitation followed by
98 gel filtration, anion exchange chromatography, and hydroxylapatite chromatography.

99 Biological Aspects

100 The DPAGT1 initiates the protein *N*-glycosylation by catalyzing the synthesis of
101 GlcNAc-P-P-dol. However, its substrates, UDP-GlcNAc and dolichol phosphate,
102 are also required for protein *O*-glycosylation, *O*-GlcNAcylation, the biosynthesis of
103 glycosylphosphatidylinositol (GPI) anchors and proteoglycans. Because of its
104 unique feature, DPAGT1 can be considered to be the key regulator of cellular
105 glycoprotein biosynthesis. *DPAGT1* gen has been found in all eukaryotes from
106 yeast to human cells. Human *DPAGT1* can complement an *alg7* conditional yeast
107 mutant (Eckert et al. 1998), demonstrating the high functional conservation
108 throughout evolution. Mutations in human *DPAGT1* cause the congenital disorder

109 of glycosylation CDG-Ij (DPAGT1-CDG) (Freeze 2006). As in yeast, mammalian
110 *ALG7* (*DPAGT1*) is essential since mice deleted for DPAGT1 are embryonic lethal
111 (Rine et al. 1983; Marek et al. 1999).

112 **Knockout and Transgenic Mice**

113 Embryos with knocked out *DPAGT1* gene can complete development through the
114 morula and blastocyst stages but die shortly after uterine implantation, demonstrat-
115 ing the essential role of this gene in early embryogenesis (Marek et al. 1999).

116 **Human Disease**

117 As the first enzyme of LLO synthetic pathway, defects of the human *DPAGT1*
118 cause CDG-Ij (DPAGT1-CDG). There are four clinical reports of five patients
119 suffering this CDG (Wu et al. 2003; Würde et al. 2012; Timal et al. 2012; Carrera
120 et al. 2012). Patients described had very severe clinical manifestations including
121 muscular hypotonia, intractable seizures, developmental delay, mental retardation,
122 and microcephaly. Most of them died within the first years of life.

123 It has been reported that mutations in *DPAGT1* also cause a Limb-Girdle congenital
124 myasthenic syndrome (CMS) (Belaya et al. 2012), an inherited disorder of neuromus-
125 cular transmission characterized by muscle weakness (Engel et al. 2012). Symptoms of
126 the patients are limited to neuromuscular function similar to those of CMSs due to
127 defects in glutamine-fructose-6-phosphate transferase 1 (GFPT1), which is involved in
128 the synthesis of UDP-*N*-acetylglucosamine (see the chapter describing *GFPT1*). It is
129 not yet clear why mutations in *DPAGT1* lead to the development of CMSs without
130 showing other nonmuscle abnormalities characteristic of DPAGT-CDGs.

131 *DPAGT1* gene is a target of the canonical Wnt/b-catenin signaling pathway
132 (Sengupta et al. 2010). Partial inhibition of *DPAGT1* reduces Wnt signaling, while
133 overexpression leads to aberrant *N*-glycosylation of E-cadherin. Hypoglycosylated
134 E-cadherin affects the stability of cadherin-mediated cell-cell adhesion and inhibits
135 Wnt signaling and *DPAGT1* expression (Nita-Lazar et al. 2009; Jamal et al. 2012).
136 Such cross talk among the *DPAGT1*/*N*-glycosylation, Wnt signaling and E-cadherin
137 adhesion is a key mechanism underlying squamous cell carcinoma (OSCC),
138 suggesting *DPAGT1* may represent an effective target for oral cancer therapy.

Au2

139 **Future Perspectives**

140 For the past few decades, enormous work has been done to elucidate the structure,
141 function, and regulation of this DPAGT1. In the post-genomic era, growing evi-
142 dence has implicated DPAGT1 in various human diseases, such as CDGs, CMSs,
143 and oral cancer. Knowing the secondary effects of protein *N*-glycosylation in other

144 regulatory pathways of the cell represents a big challenge. It will be of interest to
145 understand the molecular details of how DPAGT1 regulates the cross talk between
146 protein *N*-glycosylation and other cell essential pathways.

147 Cross-References

148 ► [Heterodimeric Alg13/Alg14 UDP-GlcNAc Transferase \(ALG13,14\)](#)

149 Further Reading

150 Lehrman (1991), Bretthauer (2009): Reviews of DPAGT1.
151 Sengupta et al. (2010): First report describing the interactions among canonical Wnt
152 signaling, DPAGT1 and E-cadherin.
153 Wurde et al. (2012): New clinical report describing DPAGT1-CDG.

154 References

Au3

- 155 Barnes G, Hansen WJ, Holcomb CL, Rine J (1984) Asparagine-linked glycosylation in
156 *Saccharomyces cerevisiae*: genetic analysis of an early step. *Mol Cell Biol* 4:2381–2388
157 Belaya K, Finlayson S, Slater CR, Cossins J, Liu WW, Maxwell S, McGowan SJ, Maslau S,
158 Twigg SR, Walls TJ, Pascual Pascual SI, Palace J, Beeson D (2012) Mutations in DPAGT1
159 cause a limb-girdle congenital myasthenic syndrome with tubular aggregates. *Am J Hum*
160 *Genet* 91(1):193–201
161 Bretthauer RK (2009) Structure, expression, and regulation of UDP-GlcNAc: dolichol phosphate
162 GlcNAc-1-phosphate transferase (DPAGT1). *Curr Drug Targets* 10(6):477–482
163 Carrera IA, Matthijs G, Perez B, Cerdá CP (2012) DPAGT1-CDG: report of a patient with fetal
164 hypokinesia phenotype. *Am J Med Genet A* 158A(8):2027–2030
165 Dan N, Middleton RB, Lehrman MA (1996) Hamster UDP-N-acetylglucosamine: dolichol-P
166 N-acetylglucosamine-1-P transferase has multiple transmembrane spans and a critical
167 cytosolic loop. *J Biol Chem* 271:30717–30724
168 Dan N, Lehrman MA (1997) Oligomerization of hamster UDP-GlcNAc:dolichol-P GlcNAc-1-P
169 transferase, an enzyme with multiple transmembrane spans. *J Biol Chem* 272:14214–14219
170 Eckert V, Blank M, Mazhari-Tabrizi R, Mumberg D, Funk M, Schwarz RT (1998) Cloning and
171 functional expression of the human GlcNAc-1-P transferase, the enzyme for the committed
172 step of the dolichol cycle, by heterologous complementation in *Saccharomyces cerevisiae*.
173 *Glycobiology* 8(1):77–85
174 Engel AG (2012) Current status of the congenital myasthenic syndromes. *Neuromuscul Disord*
175 22:566–575
176 Freeze HH (2006) Genetic defects in the human glycome. *Nat Rev Genet* 7(7):537–551
177 Heifetz A, Elbein AD (1977) Solubilization and properties of mannanose and N-acetylglucosamine
178 transferase involved in formation of polyprenyl-sugar intermediates. *J Biol Chem* 252:3057–3063
179 Helenius A, Aebi M (2004) Roles of N-linked glycans in the endoplasmic reticulum. *Annu Rev*
180 *Biochem* 73:1019–1049, Review
181 Jamal B, Sengupta PK, Gao ZN, Nita-Lazar M, Amin B, Jalisi S, Bouchie MP, Kukuruzinska MA
182 (2012) Aberrant amplification of the crosstalk between canonical Wnt signaling and
183 N-glycosylation gene DPAGT1 promotes oral cancer. *Oral Oncol* 48(6):523–529



- 184 Kaushal GP, Elbein AD (1985) Purification and properties of UDPGlcNAc: dolichyl-phosphate
185 GlcNAc-1-phosphate transferase. Activation and inhibition of the enzyme. *J Biol Chem*
186 260:16303–16309
- 187 Kean EL (1983) Influence of metal ions on the biosynthesis of *N*-acetylglucosaminyl polyprenols
188 by the retina. *Biochim Biophys Acta* 750:268–273
- 189 Kean EL (1985) Stimulation by dolichol phosphate-mannose and phospholipids of the
190 biosynthesis of *N*-acetylglucosaminylpyrophosphoryldolichol. *J Biol Chem* 260:12561–12571
- 191 Kean EL, Wei Z, Anderson VE, Zhang N, Sayre LM (1999) Regulation of the biosynthesis of
192 *N*-acetylglucosaminylpyrophosphoryldolichol, feedback and product inhibition. *J Biol Chem*
193 274:34072–34082
- 194 Kelleher DJ, Gilmore R (2006) An evolving view of the eukaryotic oligosaccharyltransferase.
195 *Glycobiology* 16(4):47R–62R, Review
- 196 Lehrman MA (1991) Biosynthesis of *N*-acetylglucosamine-P-P-dolichol, the committed step of
197 asparagine-linked oligosaccharide assembly. *Glycobiology* 1:553–562
- 198 Liu X, Chang K-P (1992) The 63-kilobase circular amplicon of tunicamycin-resistant
199 *Leishmania amazonensis* contains a functional *N*-acetylglucosamine-1-phosphate transferase
200 gene that can be used as a dominant selectable marker in transfection. *Mol Cell Biol*
201 12:4112–4122
- 202 Marek KW, Vijay IK, Marth JD (1999) A recessive deletion in the GlcNAc-1-phosphotransferase
203 gene results in peri-implantation embryonic lethality. *Glycobiology* 9(11):1263–1271
- 204 Nita-Lazar M, Noonan V, Rebutini I, Walker J, Menko AS, Kukuruzinska MA
205 (2009) Overexpression of DPAGT1 leads to aberrant *N*-glycosylation of E-cadherin and
206 cellular dis-cohesion in oral cancer. *Cancer Res* 69(14):5673–5680
- 207 Noffz C, Keppler-Ross S, Dean N (2009) Hetero-oligomeric interactions between early
208 glycosyltransferases of the dolichol cycle. *Glycobiology* 19:472–478
- 209 Plouhar PL, Bretthauer RK (1982) A phospholipid requirement for dolichol pyrophosphate
210 *N*-acetylglucosamine synthesis in phospholipase A2-treated rat lung microsomes. *J Biol*
211 *Chem* 257:8907–8911
- 212 Rajput B, Ma J, Munipappa N, Schantz L, Naylor SL, Lalley PA, Vijay IK (1992) Mouse
213 UDP-GlcNAc: dolichyl-phosphate *N*-acetylglucosaminephosphotransferase. Molecular
214 cloning of the cDNA, generation of anti-peptide antibodies and chromosomal location.
215 *Biochem J* 285:985–992
- 216 Rine J, Hansen W, Hardeman E, Davis RW (1983) Targeted selection of recombinant clones
217 through gene dosage effects. *Proc Natl Acad Sci USA* 80:6750–6754
- 218 Sengupta PK, Bouchie MP, Kukuruzinska MA (2010) *N*-glycosylation gene DPAGT1 is a target
219 of the Wnt/beta-catenin signaling pathway. *J Biol Chem* 285(41):31164–31173
- 220 Shailubhai K, Dong-Yu B, Saxena ES, Vijay IK (1988) Purification and characterization of
221 UDP-*N*-acetylglucosamine: dolichol phosphate *N*-acetyl-d-glucosamine-1-phosphate
222 transferase involved in the biosynthesis of asparagine-linked glycoproteins in the mammary
223 gland. *J Biol Chem* 263:15964–15972
- 224 Timal S, Hoischen A, Lehle L, Adamowicz M, Huijben K, Sykut-Cegielska J, Paprocka J,
225 Jamroz E, Spronsen FJV, Körner C, Gilissen C, Rodenburg RJ, Eidhof I, Heuvel LVD, Thiel
226 C, Wevers RA, Morava E, Veltman J, Lefeber DJ (2012) Gene identification in the congenital
227 disorders of glycosylation type I by whole-exome sequencing. *Hum Mol Genet* 21:4151–4161
- 228 Weerapana E, Imperiali B (2006) Asparagine-linked protein glycosylation: from eukaryotic to
229 prokaryotic systems. *Glycobiology* 16(6):91R–101R, Review
- 230 Würde AE, Reunert J, Rust S, Hertzberg C, Haverkämper S, Nürnberg G, Nürnberg P, Lehle L,
231 Rossi R, Marquardt T (2012) Congenital disorder of glycosylation type Ij (CDG-Ij,
232 DPAGT1-CDG): extending the clinical and molecular spectrum of a rare disease. *Mol Genet*
233 *Metab* 105(4):634–641
- 234 Wu X, Rush JS, Karaoglu D, Krasnewish D, Lubinsky MS, Waechter CJ et al (2003) Deficiency of
235 UDP-GlcNAc: dolichol phosphate *N*-acetylglucosamine-1 phosphate transferase (DPAGT1)
236 causes a novel congenital disorder of glycosylation type Ij. *Hum Mutat* 22:144–150

- 237 Zhu X, Lehrman MA (1990) Cloning, sequence, and expression of a cDNA encoding hamster
238 UDP-GlcNAc: dolichol phosphate N-acetylglucosamine-1-phosphate transferase. *J Biol Chem*
239 265:14250–14255
- 240 Zou J, Scoocca JR, Krag SS (1995) Asparagine-linked glycosylation in *Schizosaccharomyces*
241 *pombe*: functional conservation of the first step in oligosaccharide-lipid assembly. *Arch*
242 *Biochem Biophys* 317:487–496

Uncorrected Proof

Author Query Form

Handbook of Glycosyltransferases and Related Genes
Chapter No: 124

Query Refs.	Details Required	Author's response
AU1	"Helenius et al. (2004), Heifetz et al. (1977), and Engel et al. (2012)" are cited in text but not given in the reference list. Please provide details in the list.	
AU2	Please provide appropriate chapter number.	
AU3	Following references are not cited in text: Engel (2012), Heifetz, Elbein (1977), and Helenius, Aeby (2004).	
AU4	Please confirm if the shortened running head is fine.	